<code id='763EE71E4B'></code><style id='763EE71E4B'></style>
    • <acronym id='763EE71E4B'></acronym>
      <center id='763EE71E4B'><center id='763EE71E4B'><tfoot id='763EE71E4B'></tfoot></center><abbr id='763EE71E4B'><dir id='763EE71E4B'><tfoot id='763EE71E4B'></tfoot><noframes id='763EE71E4B'>

    • <optgroup id='763EE71E4B'><strike id='763EE71E4B'><sup id='763EE71E4B'></sup></strike><code id='763EE71E4B'></code></optgroup>
        1. <b id='763EE71E4B'><label id='763EE71E4B'><select id='763EE71E4B'><dt id='763EE71E4B'><span id='763EE71E4B'></span></dt></select></label></b><u id='763EE71E4B'></u>
          <i id='763EE71E4B'><strike id='763EE71E4B'><tt id='763EE71E4B'><pre id='763EE71E4B'></pre></tt></strike></i>

          entertainment

          entertainment

          author:fashion    Page View:7
          Alnylam headquarters
          Kristoffer Tripplaar/Sipa USA/AP

          Alnylam Pharmaceuticals said Thursday that sales of its treatments for rare diseases grew 43% in the second quarter compared to the year-ago period, as the biotech prepares for a key meeting with the Food and Drug Administration in September.

          Net product sales in the quarter were $306 million, led by Amvuttra, the company’s RNAi treatment for hereditary ATTR, with sales of $132 million, exceeding Wall Street forecasts. Sales of Onpattro, its older medicine for hereditary ATTR, were $91 million, slightly less than expectations.

          advertisement

          The FDA has scheduled a meeting of outside experts on Sept. 13 to discuss the company’s application to expand the indication for Onpattro to include ATTR-CM, a related condition that affects the heart. The FDA decision is due by Oct. 8. An expansion would open a much larger market for the drug than its current approval, which largely targets nerve-related damage.

          Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

          GET STARTED Log In

          knowledge

          Moonlake's readout produced a cash windfall. Risks remain
          Moonlake's readout produced a cash windfall. Risks remain

          MollyFerguson/STATFortwodaysstartingonSunday,MoonlakeImmunotherapeuticshappilycrunchednumbersandshar

          read more
          VC firm RA Capital starts a new synthetic biology incubator
          VC firm RA Capital starts a new synthetic biology incubator

          AdobeVenturecapitalfirmRACapitalisstartinganewincubator,settingthestageforthefirmtocreatenewstartups

          read more
          State Dept. review finds Biden bears some blame for Afghanistan failures
          State Dept. review finds Biden bears some blame for Afghanistan failures

          3:53HundredsofpeoplegathernearaU.S.AirForceC-17transportplaneattheperimeteroftheinternationalairport

          read more

          CDC concerned about possible undetected monkeypox spread in U.K.

          Amonkeypoxvirion,ascapturedinanelectronmicroscopicimage.CDC/CynthiaS.GoldsmithTheCentersforDiseaseCo